Science Sector Pulse: What Experts Think About Big Moves

The science community is currently sharing its views on what's coming next. Experts are sharing qualitative signals that reflect how they feel about upcoming developments. These aren't confirmed facts but rather the mood and expectations people have about the field.

Big tech companies are generating a lot of buzz about their potential IPO market capitalization. Some analysts think SpaceX could end up with the largest market cap in its benchmark. Others are more skeptical, with OpenAI and ByteDance facing doubts about reaching that top spot. The current mood leans toward skepticism for the latter two.

Artificial intelligence is being asked how many more complex mathematical problems it might solve. There's strong belief that AI could tackle more Millennium Prize Problems than currently known. However, some experts remain cautious, thinking the number might be lower than expected.

A skin cancer vaccine has been submitted for review by different dates. The prevailing view is positive, with many seeing a clear path to approval. Meanwhile, the CMI is considering whether to declare certain Millennium Prize Problems solved by a specific deadline. The consensus here is that this is unlikely to happen.

Regulators are also looking at a skin cancer vaccine approval timeline. Some expect it by the end of the year, while others think mid-year might be more realistic. The outlook for measles cases in the U.S. is also being discussed, though details are limited.